Edwards Lifesciences Corporation
Edwards Lifesciences Corporation Fundamental Analysis
Edwards Lifesciences Corporation (EW) shows moderate financial fundamentals with a PE ratio of 43.23, profit margin of 17.64%, and ROE of 10.47%. The company generates $6.1B in annual revenue with moderate year-over-year growth of 8.57%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze EW's fundamental strength across five key dimensions:
Efficiency Score
WeakEW struggles to generate sufficient returns from assets.
Valuation Score
ModerateEW shows balanced valuation metrics.
Growth Score
ModerateEW shows steady but slowing expansion.
Financial Health Score
ExcellentEW maintains a strong and stable balance sheet.
Profitability Score
ModerateEW maintains healthy but balanced margins.
Key Financial Metrics
Is EW Expensive or Cheap?
P/E Ratio
EW trades at 43.23 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, EW's PEG of -2.06 indicates potential undervaluation.
Price to Book
The market values Edwards Lifesciences Corporation at 4.53 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 36.16 times EBITDA. This signals the market has high growth expectations.
How Well Does EW Make Money?
Net Profit Margin
For every $100 in sales, Edwards Lifesciences Corporation keeps $17.64 as profit after all expenses.
Operating Margin
Core operations generate 26.72 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.47 in profit for every $100 of shareholder equity.
ROA
Edwards Lifesciences Corporation generates $8.06 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Edwards Lifesciences Corporation produces operating cash flow of $1.03B, showing steady but balanced cash generation.
Free Cash Flow
Edwards Lifesciences Corporation generates strong free cash flow of $813.48M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.39 in free cash annually.
FCF Yield
EW converts 1.72% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
43.23
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.53
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.004
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How EW Stacks Against Its Sector Peers
| Metric | EW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 43.23 | 29.43 | Worse (Expensive) |
| ROE | 10.47% | 800.00% | Weak |
| Net Margin | 17.64% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.07 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.00 | 4.64 | Strong Liquidity |
| ROA | 8.06% | -17936.00% (disorted) | Weak |
EW outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Edwards Lifesciences Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
30.80%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
316.90%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-51.93%
Industry Style: Defensive, Growth, Innovation
Declining